ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Long-Term Observation of Patients With Early Rheumatoid Arthritis

This study is currently recruiting participants.
Verified by University of California, Los Angeles, July 2005

Sponsored by: University of California, Los Angeles
Information provided by: University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT00240136
  Purpose

The purpose of this research is to observe the effects of RA over a long period in order to learn which of the early characteristics of patients' early RA predict future joint damage and disability. We also investigate whether certain treatments can prevent or slow the development of joint damage and disability. Additionally, the costs and effects of RA on the patient are studied in order to improve the methods used to measure these effects. Clinical, demographic, radiographic, and laboratory measures are taken by the rheumatologist in the office. In addition, patient questionnaires are mailed & completed by the patient and returned to the coordinating center at UCLA. All information obtained by these means will be studied in their effects on early, severe RA.


Condition
Rheumatoid Arthritis

MedlinePlus related topics:   Rheumatoid Arthritis   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Natural History, Longitudinal, Defined Population, Retrospective/Prospective Study
Official Title:   Long-Term Observation of Patients With Early Rheumatoid Arthritis

Further study details as provided by University of California, Los Angeles:

Estimated Enrollment:   400
Study Start Date:   January 1993
Estimated Study Completion Date:   July 2007

Detailed Description:

See Publications

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • >=6 swollen joints & >=9 tender joints
  • symmetrical rheumatoid arthritis (RA)
  • <= 2 years worth of symptoms
  • rheumatoid factor seropositivity

Exclusion Criteria:

  • <18 years old
  • Inability to see rheumatologist, complete questionnaires (lack of compliance)
  • >2 years worth of symptoms
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00240136

Contacts
Contact: Harold E Paulus, MD     310-825-6439     hpaulus@mednet.ucla.edu    
Contact: Grace S Park, MPH     310-825-6333     gspark@mednet.ucla.edu    

Locations
United States, California
UCLA     Recruiting
      Los Angeles, California, United States, 90095
      Contact: Harold E Paulus, MD     310-825-6439     hpaulus@mednet.ucla.edu    
      Sub-Investigator: Daniel E Furst, MD            
      Sub-Investigator: Betty Tsao, PhD            
      Sub-Investigator: Christina M Charles, MD            
      Sub-Investigator: Veena K Ranganath, MD            

Sponsors and Collaborators
University of California, Los Angeles

Investigators
Principal Investigator:     Harold E Paulus, MD     University of California, Los Angeles    
  More Information


Publications of Results:
Cole JC, Motivala SJ, Khanna D, Lee JY, Paulus HE, Irwin MR. Validation of single-factor structure and scoring protocol for the Health Assessment Questionnaire-Disability Index. Arthritis Rheum. 2005 Aug 15;53(4):536-42.
 
Khanna D, Ranganath VK, Fitzgerald J, Park GS, Altman RD, Elashoff D, Gold RH, Sharp JT, Furst DE, Paulus HE; Western Consortium of Practicing Rheumatologists. Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands, but not with more rapid progression of damage. Arthritis Rheum. 2005 Aug;52(8):2284-92.
 
Ranganath VK, Elashoff DA, Khanna D, Park G, Peter JB, Paulus HE; Western consortium of practicing rhuemotologists. Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients. J Rheumatol. 2005 Jun;32(6):1040-2.
 
Wu H, Khanna D, Park G, Gersuk V, Nepom GT, Wong WK, Paulus HE, Tsao BP. Interaction between RANKL and HLA-DRB1 genotypes may contribute to younger age at onset of seropositive rheumatoid arthritis in an inception cohort. Arthritis Rheum. 2004 Oct;50(10):3093-103.
 
Amjadi-Begvand S, Khanna D, Park GS, Bulpitt KJ, Wong WK, Paulus HE. Dating the "window of therapeutic opportunity" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset. J Rheumatol. 2004 Sep;31(9):1686-92.
 
Paulus HE, Oh M, Sharp JT, Gold RH, Wong WK, Park GS, Bulpitt KJ; Western Consortium of Practicing Rheumatologists. Classifying structural joint damage in rheumatoid arthritis as progressive or nonprogressive using a composite definition of joint radiographic change: a preliminary proposal. Arthritis Rheum. 2004 Apr;50(4):1083-96.
 
Paulus HE, Oh M, Sharp JT, Gold RH, Wong WK, Park GS, Bulpitt KJ; Western Consortium of Praticing Rheumatologists. Correlation of single time-point damage scores with observed progression of radiographic damage during the first 6 years of rheumatoid arthritis. J Rheumatol. 2003 Apr;30(4):705-13.
 
Paulus HE, Wiesner J, Bulpitt KJ, Patnaik M, Law J, Park GS, Wong WK. Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment. J Rheumatol. 2002 Dec;29(12):2513-20.
 
Paulus HE, Bulpitt KJ, Ramos B, Park G, Wong WK; Western Consortium of Practicing Rheumatologists. Relative contributions of the components of the American College of Rheumatology 20% criteria for improvement to responder status in patients with early seropositive rheumatoid arthritis. Arthritis Rheum. 2000 Dec;43(12):2743-50.
 
Newhall-Perry K, Law NJ, Ramos B, Sterz M, Wong WK, Bulpitt KJ, Park G, Lee M, Clements P, Paulus HE. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. J Rheumatol. 2000 May;27(5):1156-63.
 
Paulus HE, Ramos B, Wong WK, Ahmed A, Bulpitt K, Park G, Sterz M, Clements P. Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the Disease Activity Score in patients with early rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. J Rheumatol. 1999 Nov;26(11):2324-31.
 

Study ID Numbers:   91-10-435-32
First Received:   October 13, 2005
Last Updated:   April 18, 2007
ClinicalTrials.gov Identifier:   NCT00240136
Health Authority:   United States: Institutional Review Board

Keywords provided by University of California, Los Angeles:
Early, severe  

Study placed in the following topic categories:
Autoimmune Diseases
Musculoskeletal Diseases
Joint Diseases
Arthritis
Connective Tissue Diseases
Arthritis, Rheumatoid
Rheumatic Diseases

Additional relevant MeSH terms:
Immune System Diseases

ClinicalTrials.gov processed this record on October 17, 2008

U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act
U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services



Links to all studies - primarily for crawlers